NCT07570407 Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
| NCT ID | NCT07570407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Pilsen |
| Condition | Allogeneic HSCT |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2026-08-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.
Eligibility Criteria
Inclusion Criteria: * Diagnosis: AML (exlusion of secondary disease) * Disease status at time of HSCT: complete remission * Karnofsky performance status: ≥80% * Source of HSC: PBSC Exclusion Criteria: * Prior transplant * Uncontrolled Malignancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07570407 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Allogeneic HSCT. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07570407 currently recruiting?
Yes, NCT07570407 is actively recruiting participants. Contact the research team at holubovam@fnplzen.cz for enrollment information.
Where is the NCT07570407 trial being conducted?
This trial is being conducted at Pilsen, Czechia.
Who is sponsoring the NCT07570407 clinical trial?
NCT07570407 is sponsored by University Hospital Pilsen. The trial plans to enroll 75 participants.